ZHARMYN GARCIA: Open Payments
NPI 1649829979 · CUMBERLAND, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$487 in 13 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $103 · 2025 $487
Food & beverage: $487
| Company | Payments | Amount |
|---|---|---|
| Orchard Therapeutics North America | 1 | $152 |
| Chiesi USA, Inc. | 1 | $79 |
| Lundbeck LLC | 3 | $46 |
| SK Life Science, Inc. | 1 | $33 |
| ABBVIE INC. | 1 | $32 |
| Neurocrine BioSciences, Inc. | 1 | $32 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Eisai Inc. | 1 | $25 |
| EMD Serono, Inc. | 1 | $24 |
| Boston Scientific Corporation | 1 | $23 |
Products named: LENMELDY, CLEVIPREX, VYEPTI, BOTOX, INGREZZA, Symbravo, Leqembi, WATCHMAN FLX.
Industry payments across MD — which companies pay providers there.
